RVMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Revolution Medicines Inc (RVMD) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong Phase 3 trial results, consistent analyst upgrades with significant price target increases, and its leadership in the RAS inhibitor space make it a compelling long-term investment opportunity. While there are no immediate trading signals or congress trading data, the positive momentum and strong fundamentals outweigh any short-term technical concerns.
The technical indicators are mixed but lean slightly positive. The MACD is above 0 and positively contracting, suggesting bullish momentum. The RSI is neutral at 49.665, indicating no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the current price is above the pivot level of 130.153, with resistance levels at 153.482 and 167.894. However, short-term stock trends suggest potential minor pullbacks (-1% in the next week, -5.94% in the next month).
Strong Phase 3 trial results for daraxonrasib in pancreatic cancer, meeting all primary and secondary endpoints with significant survival benefits.
Analysts have significantly raised price targets (e.g., Evercore ISI to $200, Guggenheim to $175, RBC Capital to $162), reflecting high confidence in the company's future growth.
The company raised $2.225 billion through an upsized offering, providing ample funding for R&D and corporate expenses.
Positive news flow on clinical data for other pipeline drugs, such as zoldonrasib for lung cancer.
The company's financials show no revenue and a net loss of $364.89 million in Q4 2025, despite YoY improvements in net income and EPS.
No significant hedge fund or insider trading activity, indicating neutral sentiment from institutional investors.
Short-term stock trend analysis suggests potential minor declines in the next week and month.
In Q4 2025, Revolution Medicines reported no revenue, but net income improved significantly YoY by 87.54% to -$364.89 million. EPS also improved by 67.86% YoY to -1.88. While the company remains unprofitable, these improvements indicate progress in managing costs and advancing its pipeline.
Analysts are overwhelmingly positive on RVMD, with multiple firms raising price targets significantly following the RASolute 302 trial results. Evercore ISI raised its target to $200, citing the trial as a 'game-changer,' while Guggenheim, RBC Capital, and others highlight the strong survival data and potential for label expansion. The consensus rating is 'Buy' or 'Outperform,' reflecting strong confidence in the company's growth prospects.
